|

Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases

RECRUITINGSponsored by First Affiliated Hospital of Fujian Medical University
Actively Recruiting
SponsorFirst Affiliated Hospital of Fujian Medical University
Started2023-12-01
Est. completion2026-12-31
Eligibility
Age30 Years – 74 Years
Healthy vol.Accepted

Summary

68-Ga-DOTATATE is a radiotracer targeting somatostatin receptors (SSTR). In this study, we investigated the diagnostic efficacy of delayed \^68\^Ga-DOTATATE PET/MR in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and liver metastases, and performed a head-to-head comparison with conventional 68-Ga-DOTATATE PET/CT.

Eligibility

Age: 30 Years – 74 YearsHealthy volunteers accepted
Inclusion Criteria:

(a)Histologically confirmed well-differentiated GEP-NETs via biopsy or surgical resection in adults aged 18-80 years,(b) confirmed or suspected liver metastases, as determined by previous imaging studies or PET/CT scans,(c) availability of comprehensive surgical reports, pathological findings, comparative data, and clinical follow-up outcomes for analysis,(d) absence of PET/MR contraindications , with voluntary participation and signed informed consent forms adhering to ethical and research guidelines

Exclusion Criteria:

(a) unavailability of surgical, pathological or long-term follow-up data; (b) non-compliance with age eligibility criteria or presence of comorbidities compromising protocol adherence

Conditions3

CancerGastroenteropancreatic Neuroendocrine TumorsLiver Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.